Transmedica receives FDA clearance for Laser Lancet

17 Jun 2002

Transmiedica International, Inc., has received broad clearance from the U.S. Food and Drug Administration for its Laser Lancet to perforate skin to draw capillary blood for screening purposes. The Laser Lancet is a small, portable, battery-operated Er:YAG laser which eliminates the need for steel lancets and thus eliminates accidental sticks or transmission of blood-borne pathogens. The clinical data submitted to the FDA not only demonstrated the safety of the Laser Lancet but also showed that the healing rate of the skin perforation was equal to or better than perforations performed with steel lancets.